Patents by Inventor Xing Dai

Xing Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210158567
    Abstract: A visual positioning method includes: detecting a lane line of a surface based on a video stream of the road surface collected by a camera mounted on a vehicle; determining first reference point information at a current angle of view according to a detection result of the lane line; determining a third homography matrix according to the first and second reference point information at a previous angle of view of the camera, the position of a second reference point corresponds to that of a first reference point, and the third homography matrix is used for representing a mapping relationship between a coordinate of the camera at the current angle of view and a coordinate of the camera at the previous angle of view; determining a first homography matrix according to the third homography matrix and a predetermined homography matrix; and performing positioning according to the first homography matrix.
    Type: Application
    Filed: May 23, 2019
    Publication date: May 27, 2021
    Applicant: BEIJING SENSETIME TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Xing DAI, Zhe WANG, Jianping SHI
  • Patent number: 11014936
    Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: May 25, 2021
    Assignee: INVENTISBIO LLC
    Inventors: Xing Dai, Yaolin Wang
  • Patent number: 11008338
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Patent number: 10980807
    Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: April 20, 2021
    Assignee: InventisBio LLC
    Inventors: Xing Dai, Yaolin Wang
  • Patent number: 10954240
    Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R9, and A are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: March 23, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xing Dai, Kallol Basu, Duane DeMong, Sarah W. Li, Michael Miller, Jack D. Scott, Andrew W. Stamford
  • Publication number: 20210040068
    Abstract: Provided herein are compounds, salts, solid forms, and pharmaceutical compositions that are related to EGFR inhibitors, such as N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, solid forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as cancer.
    Type: Application
    Filed: May 14, 2019
    Publication date: February 11, 2021
    Inventors: Xing DAI, Yueheng JIANG
  • Publication number: 20210032204
    Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound (1) and its salts (such as sodium, potassium, and calcium salt), as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as gout and hyperuricemia.
    Type: Application
    Filed: March 26, 2019
    Publication date: February 4, 2021
    Inventors: Xing DAI, Yueheng JIANG
  • Publication number: 20210017187
    Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: January 21, 2021
    Inventors: Xing DAI, Yaolin WANG, Yueheng JIANG, Yanqin LIU, Haotao NIU, Zhenwu WANG, Zixing HAN, Liangshan TAO, Jifang WENG, Zhe SHI
  • Publication number: 20200216466
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Publication number: 20200197375
    Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 25, 2020
    Inventors: Xing DAI, Yueheng JIANG
  • Patent number: 10689401
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I) or a tautomer thereof and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: June 23, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Publication number: 20200160561
    Abstract: Vehicle-mounted camera pose estimation methods, apparatuses, and systems, and electronic devices involve performing lane line detection of a road on which a vehicle drives on the basis of a video stream of the road acquired by a vehicle-mounted camera; obtaining horizon information of the road on which the vehicle drives according to a lane line detection result; and obtaining pose information of the vehicle-mounted camera according to the horizon information.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 21, 2020
    Applicant: BEIJING SENSETIME TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Xing DAI, Zhe WANG, Jianping SHI
  • Patent number: 10647724
    Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 12, 2020
    Assignee: INVENTISBIO INC.
    Inventors: Xing Dai, Yaolin Wang
  • Patent number: 10604534
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1, R2, RA, ring A, ring C, and m are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn P. Walsh, Jared N. Cumming, Xing Dai
  • Publication number: 20200048250
    Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 13, 2020
    Inventors: Xing DAI, Yaolin WANG
  • Publication number: 20200046697
    Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: February 8, 2017
    Publication date: February 13, 2020
    Inventors: Xing DAI, Yaolin WANG
  • Publication number: 20200040001
    Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 6, 2020
    Inventors: Xing DAI, Yaolin WANG
  • Publication number: 20190040081
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1, R2, RA, ring A, ring C, and m are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: February 6, 2017
    Publication date: February 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Shawn P. Walsh, Jared N. Cumming, Xing Dai
  • Publication number: 20190016734
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I) or a tautomer thereof and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: February 6, 2017
    Publication date: January 17, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Publication number: 20180230152
    Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R9, and A are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: August 28, 2015
    Publication date: August 16, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Xing Dai, Kallol Basu, Duane DeMong, Sarah W. Li, Michael Miller, Jack D. Scott, Andrew W. Stamford